PetLife Pharmaceuticals, Inc. announced it has appointed its initial executive management team. In the weeks and months ahead, the company plans to add senior executives to management, the Board of Directors and will form a Scientific Advisory Board. Arthur G. Mikaelian has been appointed President, Chief Executive Officer and a member of the Board of Directors.

Bruce Niswander has been appointed Chief Financial Officer. Vivek Ramana has been appointed Chief Medical Officer. For the past 20 years, Dr. Mikaelian has been independently actively studying stress hormones (cortisol, epinephrine), master gene (ATF3) and their indirect influences on cancer cell activity and tumor progression.

His initial findings quickly led him to the innovative creation of a new generation of nutraceuticals and pharmaceutical drugs, as well as expanding his interests in cancer and oncology. Mr. Niswander has had over 30 years of experience in commercializing new, entrepreneurial ventures, and was previously working as Director of Economic Development Initiatives with United Nations affiliate, South-South Corporation. Prior to Mr. Niswander's work with the United Nations and GBI he spent six years on the faculty of New York University teaching Technology Entrepreneurship, Entrepreneurial Finance and Managing Intellectual Property.

Prior to joining PetLife, Dr. Ramana served as Senior Safety Medical Officer/Senior Medical Director for Ambit Biosciences. In 2008 - 2009, Dr. Ramana served as Senior Medical Director/Therapeutic Area Lead for US Astellas. From 2006 to 2008 he was Chief Medical Officer and President for AdPharma.

From 2003 to 2006, he served as Vice President, Medical Services at Ovation Pharmaceuticals.